中国卫生标准管理
中國衛生標準管理
중국위생표준관리
CHINA HEALTH STANDARD MANAGEMENT
2015年
20期
138-139
,共2页
参芪扶正注射液%化疗%肺癌%临床疗效
參芪扶正註射液%化療%肺癌%臨床療效
삼기부정주사액%화료%폐암%림상료효
Ginseng and astragalus righting injection%Chemotherapy%Lung cancer%Clinical curative effect
目的:探讨参芪扶正注射液配合化疗治疗肺癌临床疗效。方法本次研究的74例肺癌患者均为我院2014年4月~2015年3月收治,将其按照治疗方案的不同分为观察组37例和对照组37例,观察组在化疗基础上增加参芪扶正注射液治疗,对照组患者只单纯进行化疗治疗,对比两组患者的治疗效果和体力变化情况。结果观察组治疗总有效率为94.59%,KPS评分为(86.37±4.68)分;对照组治疗总有效率为32.43%,KPS评分为(55.31±6.74)分。两组治疗总有效率和KPS评分的组间比较差异有统计学意义(P<0.01)。结论参芪扶正注射液配合化疗治疗肺癌临床疗效显著,且可提升患者体力。
目的:探討參芪扶正註射液配閤化療治療肺癌臨床療效。方法本次研究的74例肺癌患者均為我院2014年4月~2015年3月收治,將其按照治療方案的不同分為觀察組37例和對照組37例,觀察組在化療基礎上增加參芪扶正註射液治療,對照組患者隻單純進行化療治療,對比兩組患者的治療效果和體力變化情況。結果觀察組治療總有效率為94.59%,KPS評分為(86.37±4.68)分;對照組治療總有效率為32.43%,KPS評分為(55.31±6.74)分。兩組治療總有效率和KPS評分的組間比較差異有統計學意義(P<0.01)。結論參芪扶正註射液配閤化療治療肺癌臨床療效顯著,且可提升患者體力。
목적:탐토삼기부정주사액배합화료치료폐암림상료효。방법본차연구적74례폐암환자균위아원2014년4월~2015년3월수치,장기안조치료방안적불동분위관찰조37례화대조조37례,관찰조재화료기출상증가삼기부정주사액치료,대조조환자지단순진행화료치료,대비량조환자적치료효과화체력변화정황。결과관찰조치료총유효솔위94.59%,KPS평분위(86.37±4.68)분;대조조치료총유효솔위32.43%,KPS평분위(55.31±6.74)분。량조치료총유효솔화KPS평분적조간비교차이유통계학의의(P<0.01)。결론삼기부정주사액배합화료치료폐암림상료효현저,차가제승환자체력。
ObjectiveTo investigate the clinical effect of ginseng and astragalus injection and chemotherapy in treatment of lung cancer.Methods74 patients with lung cancer in our hospital from April 2014 to March 2015 were treated,according to the different points of treatment plan and control group,each of 37 cases,observation group on the basis of the increase in the treatment of patients with chemotherapy,the control group were treated with chemotherapy,compared with two groups of patients with treatment effect and physical changes.Results The total effective rate of the observation group was 94.59%,the KPS score was(86.37±4.68),the total effective rate was 32.43% in the control group,and the KPS score was(55.31±6.74). The total effective rate and KPS score of the two groups were statistically significant (P< 0.01).Conclusion The clinical curative effect of ginseng and astragalus injection and chemotherapy in treatment of lung cancer is remarkable.